Bellicum Pharmaceuticals Announces Presentations of its Controllable Switch Technology Platform at the American Society of Hematology 2017 Annual Meeting

December 11, 2017 by Website Admin in

Bellicum Pharmaceuticals, Inc. today announced data highlighting results from three preclinical studies of its controllable switch technology for T cell immunotherapies.

Tweet

Share

Pin it

Previous StoryBellicum Announces Data Demonstrating Improved Immune Recovery Following Haploidentical Stem Cell Transplant in Children with Blood Cancers & Nonmalignant Diseases Next StoryRepros Therapeutics Inc.® Announces Acquisition by Allergan plc